Phenotype Annotations Click to see Annotation Detail View
Mammalian PhenotypeObject Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | LA-cp/NJcr | Rat | abnormal pancreatic islet morphology | | IAGP | | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | abnormal pancreatic islet size | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | albuminuria | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | atherosclerotic lesions | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | atherosclerotic lesions | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | glomerulosclerosis | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | hyperlipidemia | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased abdominal adipose tissue amount | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased body weight | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased body weight | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased body weight | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating cholesterol level | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating cholesterol level | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating cholesterol level | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating free fatty acids level | treatment | IAGP | Medica 16 | 21408584 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating glucose level | | IAGP | | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating HDL cholesterol level | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating insulin level | treatment | IAGP | Medica 16 | 21408584 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating insulin level | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating insulin level | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating insulin level | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating interleukin-1 beta level | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating LDL cholesterol level | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating leptin level | treatment | IAGP | Medica 16 | 21408584 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating leptin level | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating phospholipid level | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating triglyceride level | treatment | IAGP | Medica 16 | 21408584 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating triglyceride level | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating triglyceride level | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased circulating triglyceride level | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased food intake | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased food intake | | IAGP | | 1642389 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased food intake | | IAGP | | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased macrophage cell number | treatment | IAGP | Medica 16 | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased susceptibility to atherosclerosis | | IAGP | | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | increased susceptibility to atherosclerosis | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | obese | | IAGP | | 1642391 | compared to lean LA/NJcr+/+ rats | RGD | | LA-cp/NJcr | Rat | pathological neovascularization | treatment | IAGP | Benfluorex | 21408581 | compared to lean LA/NJcr+/+ rats | RGD | | | |||||||||||||||||||||||||||||


















